COMPASS Pathways’ (CMPS) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a report published on Friday morning,Benzinga reports.

A number of other analysts also recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Canaccord Genuity Group dropped their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Stifel Nicolaus assumed coverage on shares of COMPASS Pathways in a research report on Thursday, February 27th. They set a “buy” rating and a $11.00 price objective for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 target price on shares of COMPASS Pathways in a report on Wednesday, January 15th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $21.83.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $2.94 on Friday. The firm has a market capitalization of $272.46 million, a PE ratio of -1.34 and a beta of 2.29. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm has a 50-day moving average price of $3.86 and a 200 day moving average price of $4.70. COMPASS Pathways has a 52-week low of $2.88 and a 52-week high of $10.31.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, sell-side analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CMPS. China Universal Asset Management Co. Ltd. acquired a new position in COMPASS Pathways in the 4th quarter worth approximately $41,000. Wealthfront Advisers LLC purchased a new stake in shares of COMPASS Pathways in the fourth quarter valued at $43,000. Flagship Harbor Advisors LLC acquired a new stake in shares of COMPASS Pathways in the fourth quarter worth $43,000. Conservest Capital Advisors Inc. grew its holdings in shares of COMPASS Pathways by 28.9% during the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after buying an additional 3,000 shares in the last quarter. Finally, Simplify Asset Management Inc. acquired a new position in COMPASS Pathways during the fourth quarter valued at $54,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.